Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Orla Cunningham, Martin Scott, Zhaohui Sunny Zhou & William J.J. Finlay. (2021) Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. mAbs 13:1.
Read now
Read now
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, Michelle Harrison, Jianjun Zou, Lianshan Zhang, Stacey Luo, Michael Lahn, Howard Kallender, Andrea Mannucci, Catello Somma, Katherine Woods, Andreas Behren, Pablo Fernandez-Penas, Michael Millward & Tarek Meniawy. (2020) A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Design, Development and Therapy 14, pages 1177-1189.
Read now
Read now
Zhongguang Chen, Xiuhua Lu & Kelly Koral. (2020) The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 14:11, pages 1017-1024.
Read now
Read now
Ruidi Jiao, Hui Luo, Wenbo Xu & Hong Ge. (2019) Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. OncoTargets and Therapy 12, pages 6023-6032.
Read now
Read now
Articles from other publishers (31)
Yao Lin, Yuxin Lin, Xiaoping Zhong, Qingshan Chen, Shijie Tang & Jiasheng Chen. (2023) A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient. Frontiers in Oncology 13.
Crossref
Crossref
Yonglong Jin, Jinpeng Xu, Dunmin Zhuang, Lina Dong, Yang Sun, Lin Zhao & Wenjing Xiao. (2023) Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports. Frontiers in Oncology 13.
Crossref
Crossref
C. Garrett Rappazzo, Monica L. Fernández-Quintero, Andreas Mayer, Nicholas C. Wu, Victor Greiff & Jenna J. Guthmiller. (2023) Defining and Studying B Cell Receptor and TCR Interactions. The Journal of Immunology 211:3, pages 311-322.
Crossref
Crossref
Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang & Li Zhang. (2023) Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial. Frontiers in Immunology 14.
Crossref
Crossref
Sandeep, Suraj H. Shinde & Abhay H. Pande. (2023) Polyspecificity - An emerging trend in the development of clinical antibodies. Molecular Immunology 155, pages 175-183.
Crossref
Crossref
Weijie Zhang, Hao Wang, Nan Feng, Yifeng Li, Jijie Gu & Zhuozhi Wang. (2023) Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Antibody Therapeutics 6:1, pages 13-29.
Crossref
Crossref
Wenwen Xu, Hao Chen, Yiting Li, Hu Cheng, Yi Deng, Peiyan Zheng, Jingzhi Li, Lan Yang, Shiping He, Dongli Ma, Qiang Zhu, Dayong Gu, Jun Han, Baoqing Sun & Hongwei Ma. (2023) Removing Negative Impacts from Inevitable Nonreproducible and Nonspecific Antibody–Probe Interactions in Viral Serology. Analytical Chemistry.
Crossref
Crossref
Michael W. Leach & Katherine Hammerman. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology
175
230
.
Hannes Ausserwöger, Matthias M. Schneider, Therese W. Herling, Paolo Arosio, Gaetano Invernizzi, Tuomas P. J. Knowles & Nikolai Lorenzen. (2022) Non-specificity as the sticky problem in therapeutic antibody development. Nature Reviews Chemistry 6:12, pages 844-861.
Crossref
Crossref
Guili Huang, Songqing Liu, Jie Dong, Xin Xi, Rui Kong, Wenjun Li & Qian Du. (2022) PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. Frontiers in Pharmacology 13.
Crossref
Crossref
Noemi Reguart & Roxana Reyes. (2022) Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors. Journal of Thoracic Oncology 17:4, pages 477-480.
Crossref
Crossref
Dan Lu, Zepeng Xu, Ding Zhang, Min Jiang, Kefang Liu, Juanhua He, Dongli Ma, Xiaopeng Ma, Shuguang Tan, George F. Gao & Yan Chai. (2022) PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. Frontiers in Immunology 13.
Crossref
Crossref
Jiaojiao Pan, Lan Yang, Wenya Wu, Jingzhi Li, Hu Cheng, Yiting Li, Wenwen Xu, Qinghong Xue, Youxin Zhou, Daxin Peng, Jiwan Qiu & Hongwei Ma. (2022) Previously Unrecognized Nonreproducible Antibody–Probe Interactions. Analytical Chemistry 94:4, pages 1974-1982.
Crossref
Crossref
Adriana-Michelle Wolf Pérez, Nikolai Lorenzen, Michele Vendruscolo & Pietro Sormanni. 2022. Therapeutic Antibodies. Therapeutic Antibodies
57
113
.
Zhaoli Tan, Chunyan Yue, Shoujian Ji, Chuanhua Zhao, Ru Jia, Yun Zhang, Rongrui Liu, Da Li, Qian Yu, Ping Li, Zhiyuan Hu, Yanlian Yang & Jianming Xu. (2021) Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. The Oncologist 26:12, pages e2227-e2238.
Crossref
Crossref
Zheng Yan, Jialin Ma, Shuna Yao, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuang Zhao & Yanyan Liu. (2021) Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study. Frontiers in Immunology 12.
Crossref
Crossref
Lucky Ahmed, Priyanka Gupta, Kyle P. Martin, Justin M. Scheer, Andrew E. Nixon & Sandeep Kumar. (2021) Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proceedings of the National Academy of Sciences 118:37.
Crossref
Crossref
Timothy K. MacLachlan, Shari Price, Joy Cavagnaro, Laura Andrews, Diann Blanset, Mary Ellen Cosenza, Maggie Dempster, Elizabeth Galbreath, Anna Maria Giusti, Kathleen Marie Heinz-Taheny, Renaud Fleurance, Esther Sutter & Michael W. Leach. (2021) Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019. Regulatory Toxicology and Pharmacology 121, pages 104872.
Crossref
Crossref
Kyusang Hwang, Jin Hwan Yoon, Ji Hyun Lee & Sukmook Lee. (2021) Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 9:1, pages 39.
Crossref
Crossref
Kefang Liu, Shuguang Tan, Wanjun Jin, Jiawei Guan, Qingling Wang, Huan Sun, Jianxun Qi, Jinghua Yan, Yan Chai, Zhongfu Wang, Chuxia Deng & George F Gao. (2020) N‐glycosylation of PD‐1 promotes binding of camrelizumab. EMBO reports 21:12.
Crossref
Crossref
Zheng Yan, Zhi-Hua Yao, Shu-Na Yao, Hai-Ying Wang, Jun-Feng Chu, Ming Song, Shuang Zhao & Yan-Yan Liu. (2020) Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma. Immunotherapy 12:16, pages 1161-1166.
Crossref
Crossref
Kunlun Wang, Bingxu Li, Mengxi Li, Shenglei Li, Hui Yang & Ling Yuan. (2020) The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers. Frontiers in Pharmacology 11.
Crossref
Crossref
Michael Ulitzka, Stefania Carrara, Julius Grzeschik, Henri Kornmann, Björn Hock & Harald Kolmar. (2020) Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem. Protein Engineering, Design and Selection 33.
Crossref
Crossref
Qian Mei, Wenying Zhang, Yang Liu, Qingming Yang, John E.J. Rasko, Jing Nie, Jiejie Liu, Xiang Li, Liang Dong, Meixia Chen, Yan Zhang, Lu Shi, Huitao Wu & Weidong Han. (2020) Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. Clinical Cancer Research 26:17, pages 4521-4530.
Crossref
Crossref
Libin Guo, Ran Wei, Yao Lin & Hang Fai Kwok. (2020) Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective. Frontiers in Immunology 11.
Crossref
Crossref
Qing Yu & Wen-Xia Wang. (2020) Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report. World Journal of Clinical Cases 8:3, pages 624-629.
Crossref
Crossref
Jim Freeth & Jo Soden. (2020) New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening. SLAS Discovery 25:2, pages 223-230.
Crossref
Crossref
Min Meng, Wenhong Li, Xia Yang, Guanghui Huang, Zhigang Wei, Yang Ni, Xiaoying Han, Jiao Wang & Xin Ye. (2020) Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI). Journal of Cancer Research and Therapeutics 16:2, pages 327-334.
Crossref
Crossref
Lisa Kötzner, Bayard Huck, Sakshi Garg & Klaus Urbahns. 2020.
1
62
.
Jiqiao Yang, Xiujing He, Qing Lv, Jing Jing & Hubing Shi. (2019) Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Frontiers in Pharmacology 10.
Crossref
Crossref
Wenhong Li, Zhigang Wei, Xia Yang, Guanghui Huang, Xiaoying Han, Yang Ni, Jiao Wang, Min Meng, Zhigeng Zou, Qiang Wen & Xin Ye. (2019) Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer. Journal of Cancer Research and Therapeutics 15:7, pages 1624.
Crossref
Crossref